Drug Approval | April 18, 2022
Amneal achieves second U.S. biosimilars approval with Alymsys
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
Momelotinib complements GSK’s existing expertise in haematology, with Sierra Oncology anticipating US regulatory submission in Q2 this year and EU submission in the second half of 2022
The fund will take equity positions in India-focused healthcare and life sciences-related companies
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite
Haleon will have a portfolio of category-leading brands including Sensodyne, Voltaren, Panadol and Centrum
Revenue of $1.67 billion represents 8% reported growth; and up 9% on a core(basis.
In the interim, Deepak Khanna will lead Human Health International.
Key takeaways of Q3FY22 quarter & conference call highlights
The awards will be conferred to the winners at the annual summit of OPPI, scheduled on March 23-24
Subscribe To Our Newsletter & Stay Updated
